Skip to main content
Erschienen in: Indian Journal of Surgical Oncology 2/2021

03.03.2021 | Original Article

Small Bowel PCI Score as a Prognostic Factor of Ovarian Cancer Patients Undergoing Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC), a Retrospective Analysis of 130 Patients

verfasst von: Christos Iavazzo, Alexandros Fotiou, Victoria Psomiadou, Sofia Lekka, Dimitrios Katsanos, John Spiliotis

Erschienen in: Indian Journal of Surgical Oncology | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

Ovarian cancer is the leading cause of death among gynecologic malignancies. Combining cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) can benefit patients with advanced ovarian cancer. We evaluate the role of small bowel peritoneal cancer index (sb-PCI) score as a prognostic factor. We retrospectively analyzed characteristics and clinical outcomes of patients that underwent intermediate cytoreductive surgery combined with HIPEC after neoadjuvant chemotherapy and patient’s characteristics underwent debulking surgery plus HIPEC for recurrence disease. One hundred thirty patients were included. Eighty-five of them (65.4%) were treated for recurrent ovarian cancer, while 45 (34.6%) underwent intermediate cytoreductive surgery after neoadjuvant chemotherapy with a mean age of 52 years. Mean intraoperative peritoneal cancer index (PCI) was 11.84 with a mean sb-PCI score of 5.57. Univariate analysis revealed that PCI, sb-PCI, and completeness of cytoreduction (CC) were parameters that correlated significantly with overall survival, while after multivariate analysis sb-PCI and CC were identified as independent prognostic factors of survival. A statistically significant correlation between sb-PCI score and overall survival of patients with advanced ovarian cancer was revealed. Further larger future studies are required to confirm our conclusion in order to change the treatment of advanced ovarian cancer patients.
Literatur
1.
Zurück zum Zitat Ahmed SA, Abou-Taleb H, Yehia A, el Malek NAA, Siefeldein GS, Badary DM, Jabir MA (2019) The accuracy of multi-detector computed tomography and laparoscopy in the prediction of peritoneal carcinomatosis index score in primary ovarian cancer. Acad Radiol 26(12):1650–1658CrossRef Ahmed SA, Abou-Taleb H, Yehia A, el Malek NAA, Siefeldein GS, Badary DM, Jabir MA (2019) The accuracy of multi-detector computed tomography and laparoscopy in the prediction of peritoneal carcinomatosis index score in primary ovarian cancer. Acad Radiol 26(12):1650–1658CrossRef
2.
Zurück zum Zitat Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424CrossRef Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424CrossRef
3.
Zurück zum Zitat Whitwell HJ, Worthington J, Blyuss O, Gentry-Maharaj A, Ryan A, Gunu R, Kalsi J, Menon U, Jacobs I, Zaikin A, Timms JF (2020) Improved early detection of ovarian cancer using longitudinal multimarker models. Br J Cancer 122(6):847–856CrossRef Whitwell HJ, Worthington J, Blyuss O, Gentry-Maharaj A, Ryan A, Gunu R, Kalsi J, Menon U, Jacobs I, Zaikin A, Timms JF (2020) Improved early detection of ovarian cancer using longitudinal multimarker models. Br J Cancer 122(6):847–856CrossRef
4.
Zurück zum Zitat Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RHM, van der Burg MEL, Lacave AJ, Panici PB, Kenter GG, Casado A, Mendiola C, Coens C, Verleye L, Stuart GCE, Pecorelli S, Reed NS (2010) Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363(10):943–953CrossRef Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RHM, van der Burg MEL, Lacave AJ, Panici PB, Kenter GG, Casado A, Mendiola C, Coens C, Verleye L, Stuart GCE, Pecorelli S, Reed NS (2010) Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363(10):943–953CrossRef
5.
Zurück zum Zitat van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, de Hingh IHJT, van der Velden J, Arts HJ, Massuger LFAG, Aalbers AGJ, Verwaal VJ, Kieffer JM, van de Vijver KK, van Tinteren H, Aaronson NK, Sonke GS (2018) Hyperthermic Intraperitoneal chemotherapy in ovarian Cancer. N Engl J Med 378(3):230–240CrossRef van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, de Hingh IHJT, van der Velden J, Arts HJ, Massuger LFAG, Aalbers AGJ, Verwaal VJ, Kieffer JM, van de Vijver KK, van Tinteren H, Aaronson NK, Sonke GS (2018) Hyperthermic Intraperitoneal chemotherapy in ovarian Cancer. N Engl J Med 378(3):230–240CrossRef
6.
Zurück zum Zitat Fotopoulou C, Sehouli J, Mahner S, Harter P, van Nieuwenhuysen E, Gonzalez-Martin A, Vergote I, Chiva L, du Bois A (2018) HIPEC: HOPE or HYPE in the fight against advanced ovarian cancer? Ann Oncol 29(8):1610–1613CrossRef Fotopoulou C, Sehouli J, Mahner S, Harter P, van Nieuwenhuysen E, Gonzalez-Martin A, Vergote I, Chiva L, du Bois A (2018) HIPEC: HOPE or HYPE in the fight against advanced ovarian cancer? Ann Oncol 29(8):1610–1613CrossRef
7.
Zurück zum Zitat Lim MC et al (2017) Randomized trial of hyperthermic intraperitoneal chemotherapy (HIPEC) in women with primary advanced peritoneal, ovarian, and tubal cancer. J Clin Oncol 35(15_suppl):5520CrossRef Lim MC et al (2017) Randomized trial of hyperthermic intraperitoneal chemotherapy (HIPEC) in women with primary advanced peritoneal, ovarian, and tubal cancer. J Clin Oncol 35(15_suppl):5520CrossRef
8.
Zurück zum Zitat Muallem MZ, Sehouli J, Richter R, Babayeva A, Gasimli K, Parashkevova A (2020) Pre-operative serum CA125, peritoneal cancer index and intra-operative mapping score as predictors of surgical results in primary epithelial ovarian cancer. Int J Gynecol Cancer 30(1):62–66CrossRef Muallem MZ, Sehouli J, Richter R, Babayeva A, Gasimli K, Parashkevova A (2020) Pre-operative serum CA125, peritoneal cancer index and intra-operative mapping score as predictors of surgical results in primary epithelial ovarian cancer. Int J Gynecol Cancer 30(1):62–66CrossRef
9.
Zurück zum Zitat Sugarbaker PH (2015) Management of peritoneal metastases - basic concepts. J Buon 20(Suppl 1):S2–S11 Sugarbaker PH (2015) Management of peritoneal metastases - basic concepts. J Buon 20(Suppl 1):S2–S11
10.
Zurück zum Zitat Colombo N, Sessa C, du Bois A, Ledermann J, McCluggage WG, McNeish I, Morice P, Pignata S, Ray-Coquard I, Vergote I, Baert T, Belaroussi I, Dashora A, Olbrecht S, Planchamp F, Querleu D, Baert T, Banerjee S, Belaroussi I, Blecharz P, Bruchim I, Cibula D, Colombo N, Concin N, Davidson B, Dashora A, Devouassoux-Shisheboran M, du Bois A, Ferrero A, Glasspool R, González-Martin A, Heinzelmann-Schwarz V, Joly F, Kim JW, Kridelka F, Ledermann J, Lorusso D, Mahner S, McCluggage WG, McNeish I, Mikami M, Mirza MR, Morice P, Nicum S, Olbrecht S, O’Donnell DM, Pautier P, Planchamp F, Pignata S, Querleu D, Ray-Coquard I, Rodolakis A, Sehouli J, Selcukbiricik F, Sessa C, Singh N, Tan DSP, Timmerman D, Tognon G, van der Velden J, Vergote I, Witteveen PO, Zeimet AG (2019) ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease dagger. Ann Oncol 30(5):672–705 Colombo N, Sessa C, du Bois A, Ledermann J, McCluggage WG, McNeish I, Morice P, Pignata S, Ray-Coquard I, Vergote I, Baert T, Belaroussi I, Dashora A, Olbrecht S, Planchamp F, Querleu D, Baert T, Banerjee S, Belaroussi I, Blecharz P, Bruchim I, Cibula D, Colombo N, Concin N, Davidson B, Dashora A, Devouassoux-Shisheboran M, du Bois A, Ferrero A, Glasspool R, González-Martin A, Heinzelmann-Schwarz V, Joly F, Kim JW, Kridelka F, Ledermann J, Lorusso D, Mahner S, McCluggage WG, McNeish I, Mikami M, Mirza MR, Morice P, Nicum S, Olbrecht S, O’Donnell DM, Pautier P, Planchamp F, Pignata S, Querleu D, Ray-Coquard I, Rodolakis A, Sehouli J, Selcukbiricik F, Sessa C, Singh N, Tan DSP, Timmerman D, Tognon G, van der Velden J, Vergote I, Witteveen PO, Zeimet AG (2019) ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease dagger. Ann Oncol 30(5):672–705
11.
Zurück zum Zitat Mehta SS, Bhatt A, Glehen O (2016) Cytoreductive surgery and peritonectomy procedures. Indian J Surg Oncol 7(2):139–151CrossRef Mehta SS, Bhatt A, Glehen O (2016) Cytoreductive surgery and peritonectomy procedures. Indian J Surg Oncol 7(2):139–151CrossRef
12.
Zurück zum Zitat Spiliotis J, Halkia E, Lianos E, Kalantzi N, Grivas A, Efstathiou E, Giassas S (2015) Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol 22(5):1570–1575 Spiliotis J, Halkia E, Lianos E, Kalantzi N, Grivas A, Efstathiou E, Giassas S (2015) Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol 22(5):1570–1575
13.
Zurück zum Zitat Coccolini F, Campanati L, Catena F, Ceni V, Ceresoli M, Jimenez Cruz J, Lotti M, Magnone S, Napoli J, Rossetti D, de Iaco P, Frigerio L, Pinna A, Runnebaum I, Ansaloni L (2015) Hyperthermic intraperitoneal chemotherapy with cisplatin and paclitaxel in advanced ovarian cancer: a multicenter prospective observational study. J Gynecol Oncol 26(1):54–61CrossRef Coccolini F, Campanati L, Catena F, Ceni V, Ceresoli M, Jimenez Cruz J, Lotti M, Magnone S, Napoli J, Rossetti D, de Iaco P, Frigerio L, Pinna A, Runnebaum I, Ansaloni L (2015) Hyperthermic intraperitoneal chemotherapy with cisplatin and paclitaxel in advanced ovarian cancer: a multicenter prospective observational study. J Gynecol Oncol 26(1):54–61CrossRef
14.
Zurück zum Zitat Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H (2019) Ovarian cancer in the world: epidemiology and risk factors. Int J Women's Health 11:287–299CrossRef Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H (2019) Ovarian cancer in the world: epidemiology and risk factors. Int J Women's Health 11:287–299CrossRef
15.
Zurück zum Zitat Yang WL, Lu Z, Bast RC Jr (2017) The role of biomarkers in the management of epithelial ovarian cancer. Expert Rev Mol Diagn 17(6):577–591CrossRef Yang WL, Lu Z, Bast RC Jr (2017) The role of biomarkers in the management of epithelial ovarian cancer. Expert Rev Mol Diagn 17(6):577–591CrossRef
16.
Zurück zum Zitat Junor EJ, Hole DJ, McNulty L, Mason M, Young J (1999) Specialist gynaecologists and survival outcome in ovarian cancer: a Scottish national study of 1866 patients. Br J Obstet Gynaecol 106(11):1130–1136CrossRef Junor EJ, Hole DJ, McNulty L, Mason M, Young J (1999) Specialist gynaecologists and survival outcome in ovarian cancer: a Scottish national study of 1866 patients. Br J Obstet Gynaecol 106(11):1130–1136CrossRef
17.
Zurück zum Zitat JV M (1934) Tumors of the female pelvic organs. Macmillan, New York JV M (1934) Tumors of the female pelvic organs. Macmillan, New York
18.
Zurück zum Zitat Griffiths CT (1975) Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 42:101–104PubMed Griffiths CT (1975) Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 42:101–104PubMed
19.
Zurück zum Zitat du Bois A et al (2004) Consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol 16(Suppl 8):viii7–viii12 du Bois A et al (2004) Consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol 16(Suppl 8):viii7–viii12
20.
Zurück zum Zitat Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20(5):1248–1259CrossRef Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20(5):1248–1259CrossRef
21.
Zurück zum Zitat Fader AN, Rose PG (2007) Role of surgery in ovarian carcinoma. J Clin Oncol 25(20):2873–2883CrossRef Fader AN, Rose PG (2007) Role of surgery in ovarian carcinoma. J Clin Oncol 25(20):2873–2883CrossRef
22.
Zurück zum Zitat Vergote I, de Wever I, Tjalma W, van Gramberen M, Decloedt J, van Dam P (1998) Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol Oncol 71(3):431–436CrossRef Vergote I, de Wever I, Tjalma W, van Gramberen M, Decloedt J, van Dam P (1998) Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol Oncol 71(3):431–436CrossRef
23.
Zurück zum Zitat Paulsen T, Kjærheim K, KÆRN J, Tretli S, Tropé C (2006) Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals. Int J Gynecol Cancer 16(Suppl 1):11–17CrossRef Paulsen T, Kjærheim K, KÆRN J, Tretli S, Tropé C (2006) Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals. Int J Gynecol Cancer 16(Suppl 1):11–17CrossRef
24.
Zurück zum Zitat Martin-Camean M et al (2016) The role of surgery in advanced epithelial ovarian cancer. Ecancermedicalscience 10:666PubMedPubMedCentral Martin-Camean M et al (2016) The role of surgery in advanced epithelial ovarian cancer. Ecancermedicalscience 10:666PubMedPubMedCentral
25.
Zurück zum Zitat Ramachandran A, Rajanbabu A, Bagul KG, Pavithran K, Vijaykumar DK (2018) Correlation of pattern of spread and outcomes in advanced epithelial ovarian cancers. Indian J Surg Oncol 9(2):126–132CrossRef Ramachandran A, Rajanbabu A, Bagul KG, Pavithran K, Vijaykumar DK (2018) Correlation of pattern of spread and outcomes in advanced epithelial ovarian cancers. Indian J Surg Oncol 9(2):126–132CrossRef
26.
Zurück zum Zitat Braicu EI, Sehouli J, Richter R, Pietzner K, Lichtenegger W, Fotopoulou C (2012) Primary versus secondary cytoreduction for epithelial ovarian cancer: a paired analysis of tumour pattern and surgical outcome. Eur J Cancer 48(5):687–694CrossRef Braicu EI, Sehouli J, Richter R, Pietzner K, Lichtenegger W, Fotopoulou C (2012) Primary versus secondary cytoreduction for epithelial ovarian cancer: a paired analysis of tumour pattern and surgical outcome. Eur J Cancer 48(5):687–694CrossRef
27.
Zurück zum Zitat Fotopoulou C, Richter R, Braicu EI, Schmidt SC, Lichtenegger W, Sehouli J (2010) Can complete tumor resection be predicted in advanced primary epithelial ovarian cancer? A systematic evaluation of 360 consecutive patients. Eur J Surg Oncol 36(12):1202–1210CrossRef Fotopoulou C, Richter R, Braicu EI, Schmidt SC, Lichtenegger W, Sehouli J (2010) Can complete tumor resection be predicted in advanced primary epithelial ovarian cancer? A systematic evaluation of 360 consecutive patients. Eur J Surg Oncol 36(12):1202–1210CrossRef
28.
Zurück zum Zitat Suidan RS, Ramirez PT, Sarasohn DM, Teitcher JB, Mironov S, Iyer RB, Zhou Q, Iasonos A, Paul H, Hosaka M, Aghajanian CA, Leitao MM Jr, Gardner GJ, Abu-Rustum NR, Sonoda Y, Levine DA, Hricak H, Chi DS (2014) A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer. Gynecol Oncol 134(3):455–461CrossRef Suidan RS, Ramirez PT, Sarasohn DM, Teitcher JB, Mironov S, Iyer RB, Zhou Q, Iasonos A, Paul H, Hosaka M, Aghajanian CA, Leitao MM Jr, Gardner GJ, Abu-Rustum NR, Sonoda Y, Levine DA, Hricak H, Chi DS (2014) A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer. Gynecol Oncol 134(3):455–461CrossRef
29.
Zurück zum Zitat Pomel C, Jeyarajah A, Oram D, Shepherd J, Milliken D, Dauplat J, Reynolds K (2007) Cytoreductive surgery in ovarian cancer. Cancer Imaging 7:210–215CrossRef Pomel C, Jeyarajah A, Oram D, Shepherd J, Milliken D, Dauplat J, Reynolds K (2007) Cytoreductive surgery in ovarian cancer. Cancer Imaging 7:210–215CrossRef
30.
Zurück zum Zitat Sehouli J, Richter R, Braicu EI, Bühling KJ, Bahra M, Neuhaus P, Lichtenegger W, Fotopoulou C (2010) Role of secondary cytoreductive surgery in ovarian cancer relapse: who will benefit? A systematic analysis of 240 consecutive patients. J Surg Oncol 102(6):656–662CrossRef Sehouli J, Richter R, Braicu EI, Bühling KJ, Bahra M, Neuhaus P, Lichtenegger W, Fotopoulou C (2010) Role of secondary cytoreductive surgery in ovarian cancer relapse: who will benefit? A systematic analysis of 240 consecutive patients. J Surg Oncol 102(6):656–662CrossRef
31.
Zurück zum Zitat Deffieux X, Castaigne D, Pomel C (2006) Role of laparoscopy to evaluate candidates for complete cytoreduction in advanced stages of epithelial ovarian cancer. Int J Gynecol Cancer 16(Suppl 1):35–40CrossRef Deffieux X, Castaigne D, Pomel C (2006) Role of laparoscopy to evaluate candidates for complete cytoreduction in advanced stages of epithelial ovarian cancer. Int J Gynecol Cancer 16(Suppl 1):35–40CrossRef
32.
Zurück zum Zitat Chandramohan A, Thrower A, Shah N, Mohamed F (2017) Radiological predictors of complete cytoreduction in 59 patients with peritoneal mesothelioma treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at a UK referral centre. Br J Radiol 90(1079):20170361CrossRef Chandramohan A, Thrower A, Shah N, Mohamed F (2017) Radiological predictors of complete cytoreduction in 59 patients with peritoneal mesothelioma treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at a UK referral centre. Br J Radiol 90(1079):20170361CrossRef
33.
Zurück zum Zitat Mittal R, Chandramohan A, Moran B (2017) Pseudomyxoma peritonei: natural history and treatment. Int J Hyperth 33(5):511–519CrossRef Mittal R, Chandramohan A, Moran B (2017) Pseudomyxoma peritonei: natural history and treatment. Int J Hyperth 33(5):511–519CrossRef
34.
Zurück zum Zitat Esquivel J, Sticca R, Sugarbaker P, Levine E, Yan TD, Alexander R, Baratti D, Bartlett D, Barone R, Barrios P, Bieligk S, Bretcha-Boix P, Chang CK, Chu F, Chu Q, Daniel S, de Bree E, Deraco M, Dominguez-Parra L, Elias D, Flynn R, Foster J, Garofalo A, Gilly FN, Glehen O, Gomez-Portilla A, Gonzalez-Bayon L, Gonzalez-Moreno S, Goodman M, Gushchin V, Hanna N, Hartmann J, Harrison L, Hoefer R, Kane J, Kecmanovic D, Kelley S, Kuhn J, Lamont J, Lange J, Li B, Loggie B, Mahteme H, Mann G, Martin R, Misih RA, Moran B, Morris D, Onate-Ocana L, Petrelli N, Philippe G, Pingpank J, Pitroff A, Piso P, Quinones M, Riley L, Rutstein L, Saha S, Alrawi S, Sardi A, Schneebaum S, Shen P, Shibata D, Spellman J, Stojadinovic A, Stewart J, Torres-Melero J, Tuttle T, Verwaal V, Villar J, Wilkinson N, Younan R, Zeh H, Zoetmulder F, Sebbag G, Society of Surgical Oncology Annual Meeting (2007) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology. Ann Surg Oncol 14(1):128–133CrossRef Esquivel J, Sticca R, Sugarbaker P, Levine E, Yan TD, Alexander R, Baratti D, Bartlett D, Barone R, Barrios P, Bieligk S, Bretcha-Boix P, Chang CK, Chu F, Chu Q, Daniel S, de Bree E, Deraco M, Dominguez-Parra L, Elias D, Flynn R, Foster J, Garofalo A, Gilly FN, Glehen O, Gomez-Portilla A, Gonzalez-Bayon L, Gonzalez-Moreno S, Goodman M, Gushchin V, Hanna N, Hartmann J, Harrison L, Hoefer R, Kane J, Kecmanovic D, Kelley S, Kuhn J, Lamont J, Lange J, Li B, Loggie B, Mahteme H, Mann G, Martin R, Misih RA, Moran B, Morris D, Onate-Ocana L, Petrelli N, Philippe G, Pingpank J, Pitroff A, Piso P, Quinones M, Riley L, Rutstein L, Saha S, Alrawi S, Sardi A, Schneebaum S, Shen P, Shibata D, Spellman J, Stojadinovic A, Stewart J, Torres-Melero J, Tuttle T, Verwaal V, Villar J, Wilkinson N, Younan R, Zeh H, Zoetmulder F, Sebbag G, Society of Surgical Oncology Annual Meeting (2007) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology. Ann Surg Oncol 14(1):128–133CrossRef
35.
Zurück zum Zitat Elias D, Mariani A, Cloutier AS, Blot F, Goéré D, Dumont F, Honoré C, Billard V, Dartigues P, Ducreux M (2014) Modified selection criteria for complete cytoreductive surgery plus HIPEC based on peritoneal cancer index and small bowel involvement for peritoneal carcinomatosis of colorectal origin. Eur J Surg Oncol 40(11):1467–1473CrossRef Elias D, Mariani A, Cloutier AS, Blot F, Goéré D, Dumont F, Honoré C, Billard V, Dartigues P, Ducreux M (2014) Modified selection criteria for complete cytoreductive surgery plus HIPEC based on peritoneal cancer index and small bowel involvement for peritoneal carcinomatosis of colorectal origin. Eur J Surg Oncol 40(11):1467–1473CrossRef
36.
Zurück zum Zitat Rosendahl M, Harter P, Bjørn SF, Høgdall C (2018) Specific regions, rather than the entire peritoneal carcinosis index, are predictive of complete resection and survival in advanced epithelial ovarian cancer. Int J Gynecol Cancer 28(2):316–322CrossRef Rosendahl M, Harter P, Bjørn SF, Høgdall C (2018) Specific regions, rather than the entire peritoneal carcinosis index, are predictive of complete resection and survival in advanced epithelial ovarian cancer. Int J Gynecol Cancer 28(2):316–322CrossRef
37.
Zurück zum Zitat Benizri EI, Bernard JL, Rahili A, Benchimol D, Bereder JM (2012) Small bowel involvement is a prognostic factor in colorectal carcinomatosis treated with complete cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy. World J Surg Oncol 10:56CrossRef Benizri EI, Bernard JL, Rahili A, Benchimol D, Bereder JM (2012) Small bowel involvement is a prognostic factor in colorectal carcinomatosis treated with complete cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy. World J Surg Oncol 10:56CrossRef
38.
Zurück zum Zitat Konigsrainer I et al (2014) Initial clinical experience with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in signet-ring cell gastric cancer with peritoneal metastases. J Gastric Cancer 14(2):117–122CrossRef Konigsrainer I et al (2014) Initial clinical experience with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in signet-ring cell gastric cancer with peritoneal metastases. J Gastric Cancer 14(2):117–122CrossRef
39.
Zurück zum Zitat Glehen O et al (2010) Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol 17(9):2370–2377CrossRef Glehen O et al (2010) Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol 17(9):2370–2377CrossRef
Metadaten
Titel
Small Bowel PCI Score as a Prognostic Factor of Ovarian Cancer Patients Undergoing Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC), a Retrospective Analysis of 130 Patients
verfasst von
Christos Iavazzo
Alexandros Fotiou
Victoria Psomiadou
Sofia Lekka
Dimitrios Katsanos
John Spiliotis
Publikationsdatum
03.03.2021
Verlag
Springer India
Erschienen in
Indian Journal of Surgical Oncology / Ausgabe 2/2021
Print ISSN: 0975-7651
Elektronische ISSN: 0976-6952
DOI
https://doi.org/10.1007/s13193-021-01304-w

Weitere Artikel der Ausgabe 2/2021

Indian Journal of Surgical Oncology 2/2021 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.